Determining Prognostic Immune Markers in Patients With Ovarian Cancer

Determining Prognostic Immune Markers in Patients With Ovarian Cancer

The IMPRoVE study is a prospective, non-interventional, explorative cohort study to determine prognostic immune markers in patients with epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer (EOC).

Tumor material, ascites (if possible) and blood samples for immune monitoring will be collected from patients with primary and recurrent EOC undergoing surgery, chemotherapy and/or immunotherapy.

Inclusion Criteria:

• Patients with (suspicion of) primary or recurrent EOC with an indication for surgery, chemotherapy and/or immunotherapy.
• Age ≥18 years.
• WHO performance status 0-2.
• Accessible for treatment and follow-up.
• Written informed consent.

Exclusion Criteria:

• Other active malignancy in past 5 years prior to entry into the study, except for treated non-melanoma skin cancer.
• Any known severe infection like HIV, hepatitis A, B and C.
• Receiving immune suppressive treatment.
• Medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent.